IGF1 and cancer: Studies have shown that interactions between tumor-associated macrophages and cancer-associated fibroblasts (CAFs) can enable cancer cells to develop resistance to gemcitabine and paclitaxel in pancreatic and breast cancers, primarily through IGF-1/2 signaling pathways [23,24].